Olumiant ® (baricitinib) tablets

1mg, 2mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

OLUMIANT® (baricitinib): Reproductive Risks in Males

In animal studies, baricitinib did not have an effect on male reproductive organs or sperm endpoints. However, there is a potential to decrease male fertility.

Prescribing Information

See important safety information, including boxed warning, in the attached prescribing information.

Combined Male and Female Animal Fertility Study

Male rats were treated with 0, 5, 15, or 50 mg/kg of BARI daily for 6 weeks including 4 weeks prior to cohabitation with female rats treated with 0, 5, 25, or 100 mg/kg.1

Effects on Reproductive Organs and Sperm

Histologic studies found no change in male reproductive organs, and no effects on sperm motility, concentration, and morphology at any BARI dose level.1

Effects on Fertility and Early Embryonic Development

Results by Doses

At doses of 50 and 100 mg/kg/day (approximately 113 and 169 times the MRHD), reproductive performance was unaffected in males and females. However, fertility was reduced in BARI-treated females compared to control females. Non-gravid rates were

  • 7 of 19 (36.8%) in BARI-treated females, and

  • 1 of 19 (5.3%) in control females.2

At doses of 15 mg/kg and 25 mg/kg (approximately 25 and 48 times the MRHD), fertility was unaffected in male and female rats. However, maintenance of pregnancy was adversely affected at these doses based upon findings of

  • increased post-implantation losses (early resorptions), and

  • decreased numbers of mean viable embryos per litter.2

At doses of 5mg/kg/day (approximately 8 times the MRHD), the number of viable embryos was unaffected in BARI-treated female rats that were mated to BARI-treated males.2

Potential Cause of Decreased Fertility

Based on the study design, it could not be determined if fertility results were attributable to toxicities in one sex or both. However, since there were no effects on spermatogenesis or semen/sperm endpoints in male rats, the decreased overall mating performance was likely the result of fertility effects in female rats including

  • decreased corpora lutea and implantation sites,

  • increased pre-implantation loss, and

  • adverse effects on intrauterine survival.1

Contraceptive Criteria in Clinical Trial Protocols

In BARI rheumatoid arthritis clinical trials, male patients agreed to use 2 forms of highly effective birth control while engaging in sexual intercourse with female partners of childbearing potential during the trial and for 28 days after the last dose of study medication.1

Enclosed Prescribing Information

OLUMIANT® (baricitinib) tablets, for oral use, Lilly


1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


BARI = baricitinib

MRHD = maximum recommended human dose

Date of Last Review: March 26, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical